Literature DB >> 24761791

A review of the management of childhood immune thrombocytopenia: how can we provide an evidence-based approach?

Nichola Cooper1.   

Abstract

Most children with immune thrombocytopenia (ITP) have transiently low platelet counts and do not suffer from bleeding. Treatments with steroids, immunosuppression or splenectomy are not thought to be curative and may create more problems than the low platelet count. Consequently, many children do not receive treatment unless there is bleeding. However, although registry data looks promising, this approach outcome is not consistent between countries, or even between centres in the same country, leading to confusion for both physicians and families. Reaching a consensus for the management of paediatric ITP is further complicated by the lack of a diagnostic test and by the heterogeneity of the disease; for example, although most children remain relatively asymptomatic and go into an early remission, some patients have significant bleeding and others do not go into spontaneous remission. This review assesses the available evidence to guide physicians and families on making management decisions, showing the wide range of treatment choices, and the different approaches between countries and considers methods by which further information could be acquired to provide a more stratified approach to management.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  paediatric immune thrombocytopenia; rituximab; splenectomy; thrombocytopenia; thrombopoietin

Mesh:

Year:  2014        PMID: 24761791     DOI: 10.1111/bjh.12889

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  The management of immune thrombocytopenic purpura.

Authors:  B I Chosamata
Journal:  Malawi Med J       Date:  2015-09       Impact factor: 0.875

2.  The child with immune thrombocytopenia: to treat or not to treat, is that still the question?

Authors:  Nichola Cooper; Douglas B Cines
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

3.  Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).

Authors:  James B Bussel; Loan Hsieh; George R Buchanan; Kimo Stine; Ram Kalpatthi; David J Gnarra; Richard H Ho; Kun Nie; Melissa Eisen
Journal:  Pediatr Blood Cancer       Date:  2014-10-24       Impact factor: 3.167

Review 4.  The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach.

Authors:  Rita Consolini; Giorgio Costagliola; Davide Spatafora
Journal:  Front Pediatr       Date:  2017-08-21       Impact factor: 3.418

5.  Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

Authors:  Michael D Tarantino; James B Bussel; Victor S Blanchette; Donald Beam; John Roy; Jenny Despotovic; Ashok Raj; Nancy Carpenter; Bhakti Mehta; Melissa Eisen
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

Review 6.  Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases.

Authors:  Giuseppe Leone; Eligio Pizzigallo
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-10-13       Impact factor: 2.576

7.  Clinical course and prognostic factors of childhood immune thrombocytopenia: single center experience of 10 years.

Authors:  Jae Yeob Jung; A Rum O; Je Keong Kim; Meerim Park
Journal:  Korean J Pediatr       Date:  2016-08-24

Review 8.  Management of immune thrombocytopenia: Korean experts recommendation in 2017.

Authors:  Jun Ho Jang; Ji Yoon Kim; Yeung-Chul Mun; Soo-Mee Bang; Yeon Jung Lim; Dong-Yeop Shin; Young Bae Choi; Ho-Young Yhim; Jong Wook Lee; Hoon Kook
Journal:  Blood Res       Date:  2017-12-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.